Life Style

7-day average of US COVID metrics drops to new lows

Daily 7-day average Coronavirus According to official data from the US government, the number of deaths, cases, and hospitalizations in the United States was the lowest ever.

At a regular press conference by the White House’s COVID-19 response team and public health authorities on Thursday, CDC director Dr. Rochelle Warrensky quoted the latest CDC data to significantly result in the fight against the pandemic. Announcing an improved image.

Walensky said the CDC reported more than 9,300 new cases of new coronavirus infections on Wednesday, with an average of about 15,600 cases per day for seven days. This represents a decrease of more than 30% from the average for the last 7 days. “More importantly, it’s a 94% reduction from the peak of COVID-19 cases reported in January of this year,” Dr. Glensky told reporters.

The average 7-day new hospitalization is approximately 2,750. This is an 83% reduction in hospitalizations from the peak of approximately 16,500 hospitalizations for the seven days reported on January 9.

The average 7-day death toll per day also fell to a new low of 363 per day, down more than 16% from last week.

According to the latest data from Johns Hopkins University, 17821 new cases of coronavirus were reported in the United States on Thursday, bringing the national total to 34,174,752.

On the same day, 574 new deaths were reported in the country. This has increased the number of COVID deaths in the United States to 611,611.

To date, a total of 28,025,575 people have recovered from infections in the country.

The CDC director said on Friday that the CDC will publish a report on its morbidity and mortality weekly report on the nasty data on the increased hospitalization of adolescents due to COVID-19.

At a press conference on Thursday, the president’s chief medical adviser, Dr. Anthony Fauci, provided important information about the treatment of the disease.

He used the monoclonal antibody sotrobimab at 500 mg in a randomized, placebo-controlled phase 3 study in non-hospitalized patients with mild to moderate COVID-19 who were at high risk of disease progression. A single dose reduces the risk of hospitalization or death by 85% compared to placebo.

The antibody, which was tried in approximately 600 patients, was produced by GSK and Vir.

Infectious disease specialists advised doctors that this is an important option for early treatment to prevent patients from going to the hospital.

For comments and feedback, please contact us at

Health news

7-day average of US COVID metrics drops to new lows

Source link 7-day average of US COVID metrics drops to new lows

Back to top button